ea0011p179 | Clinical practise and governance | ECE2006
Maher KT
, Drake WM
, Besser GM
, Grossman AB
, Chew SL
, Jenkins PJ
, Kalingag LA
, Fode FK
, OSullivan-Hawketts MT
, Walker DM
, Monson JP
The preparation of Sandostatin LAR® injections using a 2 ml ampoule of vehicle solution may be associated with some technical difficulties of administration, with adverse consequences for patients. The development of a 2.5 ml prefilled syringe may alleviate some of these problems. We have compared these two methods of Sandostatin LAR® administration in 17 patients with acromegaly and 5 patients with neuro-endocrine tumours, (6 drug naïve, 1...